The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

AIDS

Volumn 13, Issue 14, 1999, Pages

  Van Heeswijk, Rolf P G ^a   Veldkamp, Agnes I ^a   Hoetelmans, Richard M W ^a   Mulder, Jan W ^a   Schreij, Gerrit ^b   Hsu, Ann ^c   Lange, Joep M A ^d   Beijnen, Jos H ^a   Meenhorst, Pieter L ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ABBOTT LABORATORIES   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Drug interaction; Indinavir; Pharmacokinetics; Ritonavir

Indexed keywords

ACICLOVIR; CLARITHROMYCIN; COTRIMOXAZOLE; DIDANOSINE; FLUCONAZOLE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPERAMIDE; NEVIRAPINE; OMEPRAZOLE; RITONAVIR; STAVUDINE; TEMAZEPAM; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

ADULT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RITONAVIR;

EID: 0032710406     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910010-00001     Document Type: Article

References (16)

1. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988, 85:4686-4690.
2. Waldman SA, Teppler H, Osborne B, et al. Pharmacokinetics of L-735,524, an HIV protease inhibitor. Clin Pharmacol Ther 55:195 (abstract PIII-52).
3. Hsu A, Granneman R, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997, 41:898-905.
4. Anonymous. Ritonavir package insert. July 31, 1998, Abbotts House, Maidenhead, Berkshire, UK.
5. Kempf D, Marsh KC, Kumar C, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997, 41:654-660.
6. Hsu A, Granneman CR, Japour A, et al. Evaluation of potential ritonavir and indinavir combination bid regimens. Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 1997 [abstract A-57].
7. Lee CGL, Gottesman MM. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 1998, 101:287-288.
8. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
9. Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Exp Opin Invest Drugs 1998, 7:413-426.
10. van Heeswijk RPC, Hoetelmans RMW, Harms R, et al. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998, 719:159-168.
11. Gibaldi M. 1991. Biopharmaceutics and clinical pharmacokinetics, 4th edn. Lea & Febiger. Philadelphia, PA: 1991:14-23.
12. Boissel JP, Meillard O, Perrin-Fayolle E, et al. Comparison between a bid and a tid regimen: improved compliance with no improved antihypertensive effect. Eur J Clin Pharmacol 1996, 50:63-67.
13. Burger DM, Hoetelmans RMW, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Ther 1999, 3:215-220.
14. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urologic complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999, 13:473-478.
15. Anon. Merck abandons twice-daily Crixivan. SCRIP World Pharmaceutical News, vol. 2373. Richmond, UK: PJB Publications; 1998:15.
16. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995, 333:1528-1533